TY - JOUR
T1 - Hidden mutations in Cornelia de Lange syndrome limitations of sanger sequencing in molecular diagnostics
AU - Braunholz, Diana
AU - Obieglo, Carolin
AU - Parenti, Ilaria
AU - Pozojevic, Jelena
AU - Eckhold, Juliane
AU - Reiz, Benedikt
AU - Brænne, Ingrid
AU - Wendt, Kerstin S.
AU - Watrin, Erwan
AU - Vodopiutz, Julia
AU - Rieder, Harald
AU - Gillessen-Kaesbach, Gabriele
AU - Kaiser, Frank J.
PY - 2015/1/1
Y1 - 2015/1/1
N2 - Cornelia de Lange syndrome (CdLS) is a well-characterized developmental disorder. The genetic cause of CdLS is a mutation in one of five associated genes (NIPBL, SMC1A, SMC3, RAD21, and HDAC8) accounting for about 70% of cases. To improve our current molecular diagnostic and to analyze some of CdLS candidate genes, we developed and established a gene panel approach. Because recent data indicate a high frequency of mosaic NIPBL mutations that were not detected by conventional sequencing approaches of blood DNA, we started to collect buccal mucosa (BM) samples of our patients that were negative for mutations in the known CdLS genes. Here, we report the identification of three mosaic NIPBL mutations by our high-coverage gene panel sequencing approach that were undetected by classical Sanger sequencing analysis of BM DNA. All mutations were confirmed by the use of highly sensitive SNaPshot fragment analysis using DNA from BM, urine, and fibroblast samples. In blood samples, we could not detect the respective mutation. Finally, in fibroblast samples from all three patients, Sanger sequencing could identify all the mutations. Thus, our study highlights the need for highly sensitive technologies in molecular diagnostic of CdLS to improve genetic diagnosis and counseling of patients and their families.
AB - Cornelia de Lange syndrome (CdLS) is a well-characterized developmental disorder. The genetic cause of CdLS is a mutation in one of five associated genes (NIPBL, SMC1A, SMC3, RAD21, and HDAC8) accounting for about 70% of cases. To improve our current molecular diagnostic and to analyze some of CdLS candidate genes, we developed and established a gene panel approach. Because recent data indicate a high frequency of mosaic NIPBL mutations that were not detected by conventional sequencing approaches of blood DNA, we started to collect buccal mucosa (BM) samples of our patients that were negative for mutations in the known CdLS genes. Here, we report the identification of three mosaic NIPBL mutations by our high-coverage gene panel sequencing approach that were undetected by classical Sanger sequencing analysis of BM DNA. All mutations were confirmed by the use of highly sensitive SNaPshot fragment analysis using DNA from BM, urine, and fibroblast samples. In blood samples, we could not detect the respective mutation. Finally, in fibroblast samples from all three patients, Sanger sequencing could identify all the mutations. Thus, our study highlights the need for highly sensitive technologies in molecular diagnostic of CdLS to improve genetic diagnosis and counseling of patients and their families.
UR - https://www.scopus.com/pages/publications/84920180550
U2 - 10.1002/humu.22685
DO - 10.1002/humu.22685
M3 - Journal articles
C2 - 25196272
AN - SCOPUS:84920180550
SN - 1059-7794
VL - 36
SP - 26
EP - 29
JO - Human Mutation
JF - Human Mutation
IS - 1
ER -